AHSCT

Cecilia BrownMyeloma | November 22, 2022
A triplet treatment plus autologous stem-cell transplantation was associated with longer progression...
Leah SherwoodMyeloma | November 16, 2022
The data were from the phase III DETERMINATION trial...
Leah SherwoodMyeloma | November 16, 2022
Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over...
Advertisement
Leah SherwoodPrint | November 22, 2022
In second-line therapy for relapsed/refractory LBCL, which patients would you consider eligible for CAR T-cell therapy...
Leah SherwoodTransplantation & Cellular Therapy | November 14, 2022
The CAR T-cell therapy received accelerated approval for adults with R/R FL after two or more lines of systemic therapy.
Cecilia BrownTransplantation & Cellular Therapy | November 22, 2022
Patients with newly diagnosed primary central nervous system lymphoma who received high-dose chemotherapy and autologous ...
Advertisement
Leah SherwoodAggressive B-Cell Lymphoma | November 22, 2022
The European Medicines Agency validated a type II variation for the extension of the indication for lisocabtagene maraleucel ...
Leah SherwoodTransplantation & Cellular Therapy | November 14, 2022
In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ...
Leah LawrencePrint | November 14, 2022
Clinicians who specialize in BPDCN discuss the disease and novel therapeutic approaches to treating patients with BPCDN.
Leah LawrenceTransplantation & Cellular Therapy | November 14, 2022
Autologous hematopoietic stem cell transplantation improved survival outcomes for certain patients younger than 65.
Leah LawrenceHodgkin Lymphoma | November 14, 2022
Long-term lymphoma survivors who underwent transplant had impaired health-related quality of life.
Advertisement
Advertisement